Alexander Cumbo Sells 80,258 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

02 Feb 2026, 21:22 by Teresa Graham · The Cerbat Gem

Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) CEO Alexander Cumbo sold 80,258 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $516,861.52. Following the sale, the chief executive officer owned 270,931 shares of the company’s stock, valued at $1,744,795.64. This trade represents a 22.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alexander Cumbo also recently made the following trade(s):

On Monday, February 2nd, Alexander Cumbo sold 80,258 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total value of $516,861.52.
On Wednesday, December 3rd, Alexander Cumbo sold 10,808 shares of Solid Biosciences stock. The shares were sold at an average price of $5.11, for a total value of $55,228.88.

Solid Biosciences Price Performance

Shares of Solid Biosciences stock traded down $0.03 on Monday, hitting $6.43. 1,032,732 shares of the company’s stock traded hands, compared to its average volume of 984,289. The firm’s 50-day moving average price is $5.75 and its two-hundred day moving average price is $5.71. The stock has a market capitalization of $500.96 million, a PE ratio of -2.58 and a beta of 2.67. Solid Biosciences Inc. has a one year low of $2.41 and a one year high of $7.37.

Solid Biosciences (NASDAQ:SLDB – Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, analysts forecast that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SLDB has been the subject of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a report on Wednesday, January 14th. Chardan Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a research note on Tuesday, November 4th. Wall Street Zen downgraded Solid Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, October 19th. JPMorgan Chase & Co. dropped their price objective on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.70.

Read Our Latest Stock Report on Solid Biosciences

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

Positive Sentiment: Analysts maintain a constructive view — SLDB has an average analyst rating of “Moderate Buy,” which may support demand despite near-term weakness. Analyst Rating Article
Neutral Sentiment: Technical/market context is mixed — trading volume is slightly above average and the share price is within its 52-week range ($2.41–$7.37), suggesting limited directional conviction from broader market participants. (Market data referenced.)
Negative Sentiment: Large, concurrent insider selling — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan and other insiders) sold sizable positions on Feb 2 at an average price of $6.44. Combined disclosed sales total roughly 226k shares for about $1.45M, with individual position reductions in the ~20–25% range — a signal that could weigh on investor sentiment and share demand. Representative SEC filings: CEO Filing CTO Filing

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc grew its stake in shares of Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after purchasing an additional 4,534 shares in the last quarter. Creative Planning acquired a new position in shares of Solid Biosciences during the second quarter valued at about $57,000. Russell Investments Group Ltd. raised its stake in shares of Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after purchasing an additional 5,991 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in Solid Biosciences by 233.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after buying an additional 10,585 shares in the last quarter. 81.46% of the stock is owned by institutional investors.

About Solid Biosciences

(Get Free Report)

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.